Several studies have proven that CD8+ T cells can be used to predict the response to treatment during the neoadjuvant chemotherapy phase, particularly in the triple-negative and HER2-positive breast cancer subtypes (29–31). The gene discussed is ERBB2; the disease is breast carcinoma.